New and emerging agents for the treatment of castration-resistant prostate cancer

Urologic Oncology: Seminars and Original Investigations

Volumn 29, Issue 6 SUPPL., 2011, Pages 1-8

  Higano, Celestia S ^a   Crawford, E David ^b  

^a UNIVERSITY OF WASHINGTON SCHOOL OF MEDICINE   (United States)

^b UNIVERSITY OF COLORADO   (United States)

Author keywords

Castration resistant; Prostate cancer; Treatments

Indexed keywords

4 [3 [4 CYANO 3 (TRIFLUOROMETHYL)PHENYL] 5,5 DIMETHYL 4 OXO 2 THIOXO 1 IMIDAZOLIDINYL] 2 FLUORO N METHYLBENZAMIDE; ABIRATERONE; AFLIBERCEPT; ALPHARADIN; ATRASENTAN; BEVACIZUMAB; CABAZITAXEL; CALCITRIOL; CUSTIRSEN; DASATINIB; DENOSUMAB; DOCETAXEL; ESTRAMUSTINE; GRANULOCYTE MACROPHAGE COLONY STIMULATING FACTOR VACCINE; IPILIMUMAB; LENALIDOMIDE; LEXIDRONAM SAMARIUM SM 153; MITOXANTRONE; ORTERONEL; PREDNISONE; PROVENGE; RADIOPHARMACEUTICAL AGENT; RADIUM 223; STRONTIUM 89; UNCLASSIFIED DRUG; ZIBOTENTAN; ZOLEDRONIC ACID;

ASYMPTOMATIC DISEASE; BONE MARROW TOXICITY; CANCER CHEMOTHERAPY; CANCER GROWTH; CANCER HORMONE THERAPY; CANCER IMMUNOTHERAPY; CANCER STAGING; CANCER SURVIVAL; CASTRATION RESISTANT PROSTATE CANCER; CHEMORADIOTHERAPY; CHILL; COLITIS; CONSTIPATION; DIARRHEA; DRUG ACTIVITY; DRUG DOSE REDUCTION; DRUG ERUPTION; DRUG INDUCED HEADACHE; DRUG SAFETY; ENDOCRINE DISEASE; FATIGUE; FEBRILE NEUTROPENIA; FEVER; FLU LIKE SYNDROME; FLUID RETENTION; FOLLOW UP; GLEASON SCORE; HEART DISEASE; HEPATITIS; HUMAN; HYPERHIDROSIS; HYPERTENSION; HYPOCALCEMIA; HYPOKALEMIA; JAW OSTEONECROSIS; LEUKAPHERESIS; LIVER FUNCTION TEST; LOW DRUG DOSE; MYALGIA; NAUSEA; NEUTROPENIA; OVERALL SURVIVAL; PAIN; PERIPHERAL BLOOD MONONUCLEAR CELL; PHASE 1 CLINICAL TRIAL (TOPIC); PHASE 3 CLINICAL TRIAL (TOPIC); PRIORITY JOURNAL; PROGRESSION FREE SURVIVAL; PRURITUS; QUALITY OF LIFE; RANDOMIZED CONTROLLED TRIAL (TOPIC); RETROSPECTIVE STUDY; REVIEW; SEIZURE; SIDE EFFECT;

ANTINEOPLASTIC AGENTS; CASTRATION; CLINICAL TRIALS AS TOPIC; HUMANS; MALE; NEOPLASMS, HORMONE-DEPENDENT; PROSTATIC NEOPLASMS;

EID: 80755169423     PISSN: 10781439     EISSN: 18732496     Source Type: Journal    
DOI: 10.1016/j.urolonc.2011.08.013     Document Type: Review

References (60)

1. Siegel R., Ward E., Brawley O., et al. Cancer statistics, 2011: The impact of eliminating socioeconomic and racial disparities on premature cancer deaths. CA Cancer J Clin 2011, 61:212-236.
2. Treatment and survival of patients with cancer of the prostate. The Veterans Administration Cooperative Urological Research Group. Surg Gynecol Obstet 1967, 124:1011-1017.
3. Byar D.P. Proceedings: The Veterans Administration Cooperative Urological Research Group's studies of cancer of the prostate. Cancer 1973, 32:1126-1130.
4. Huggins C., Hodges C.V. Studies of prostatic cancer. I. The effect of castration, of estrogen and of androgen injection on serum phosphatases in metastatic carcinoma of the prostate. Cancer Research 1941, 1:293-297.
5. Huggins C., Stevens R.E., Hodges C.V. Studies of prostatic cancer. II. The effects of castration on advanced carcinoma of the prostate gland. Archives of Surgery 1941, 43:209-223.
6. Huggins C. Endocrine-induced regression of cancers. Science 1967, 156:1050-1054.
7. Byar D.P., Corle D.K. Hormone therapy for prostate cancer: Results of the Veterans Administration Cooperative Urological Research Group studies. NCI Monogr 1988, 165-170.
8. Loblaw D.A., Mendelson D.S., Talcott J.A., et al. American Society of Clinical Oncology recommendations for the initial hormonal management of androgen-sensitive metastatic, recurrent, or progressive prostate cancer. J Clin Oncol 2004, 22:2927-2941.
9. de Voogt H.J., Smith P.H., Pavone-Macaluso M., et al. Cardiovascular side effects of diethylstilbestrol, cyproterone acetate, medroxyprogesterone acetate and estramustine phosphate used for the treatment of advanced prostatic cancer: Results from European Organization for Research on Treatment of Cancer trials 30761 and 30762. J Urol 1986, 135:303-307.
10. Schally A.V., Arimura A., Kastin A.J., et al. Gonadotropin-releasing hormone: One polypeptide regulates secretion of luteinizing and follicle-stimulating hormones. Science 1971, 173:1036-1038.
11. Tolis G., Ackman D., Stellos A., et al. Tumor growth inhibition in patients with prostatic carcinoma treated with luteinizing hormone-releasing hormone agonists. Proc Natl Acad Sci U S A 1982, 79:1658-1662.
12. Seidenfeld J., Samson D.J., Hasselblad V., et al. Single-therapy androgen suppression in men with advanced prostate cancer: A systematic review and meta-analysis. Ann Intern Med 2000, 132:566-577.
13. Klotz L., Boccon-Gibod L., Shore N.D., et al. The efficacy and safety of degarelix: A 12-month, comparative, randomized, open-label, parallel-group phase III study in patients with prostate cancer. BJU Int 2008, 102:1531-1538.
14. McLeod D., Zinner N., Tomera K., et al. A phase 3, multicenter, open-label, randomized study of abarelix vs. leuprolide acetate in men with prostate cancer. Urology 2001, 58:756-761.
15. Trachtenberg J., Gittleman M., Steidle C., et al. A phase 3, multicenter, open label, randomized study of abarelix vs. leuprolide plus daily anti-androgen in men with prostate cancer. J Urol 2002, 167:1670-1674.
16. Attar R.M., Takimoto C.H., Gottardis M.M. Castration-resistant prostate cancer: Locking up the molecular escape routes. Clin Cancer Res 2009, 15:3251-3255.
17. Mostaghel E.A., Montgomery B., Nelson P.S. Castration-resistant prostate cancer: Targeting androgen metabolic pathways in recurrent disease. Urol Oncol 2009, 27:251-257.
18. Scher H.I., Heller G. Clinical states in prostate cancer: Toward a dynamic model of disease progression. Urology 2000, 55:323-327.
19. NCCN Clinical Practice Guidelines in Oncology: Prostate Cancer - V. 1.2011 National Comprehensive Cancer Network Physician Guidelines, Last Update: 2011, Accessed Jan 24, 2011. http://www.nccn.org/professionals/physician_gls/f_guidelines.asp.
20. Burch P.A., Breen J.K., Buckner J.C., et al. Priming tissue-specific cellular immunity in a phase I trial of autologous dendritic cells for prostate cancer. Clin Cancer Res 2000, 6:2175-2182.
21. Small E.J., Fratesi P., Reese D.M., et al. Immunotherapy of hormone-refractory prostate cancer with antigen-loaded dendritic cells. J Clin Oncol 2000, 18:3894-3903.
22. Goldstein N.S. Immunophenotypic characterization of 225 prostate adenocarcinomas with intermediate or high Gleason scores. Am J Clin Pathol 2002, 117:471-477.
23. Kantoff P.W., Higano C.S., Shore N.D., et al. Sipuleucel-T immunotherapy for castration-resistant prostate cancer. N Engl J Med 2010, 363:411-422.
24. Small E.J., Schellhammer P.F., Higano C.S., et al. Placebo-controlled phase III trial of immunologic therapy with sipuleucel-T (APC8015) in patients with metastatic, asymptomatic hormone refractory prostate cancer. J Clin Oncol 2006, 24:3089-3094.
25. Higano C.S., Schellhammer P.F., Small E.J., et al. Integrated data from 2 randomized, double-blind, placebo-controlled, phase 3 trials of active cellular immunotherapy with sipuleucel-T in advanced prostate cancer. Cancer 2009, 115:3670-3679.
26. Higano CS, Small EJ, Schellhammer PF, et al. Predictors of outcome and subgroup results from the integrated analysis of sipuleucel-T trials in metastatic castration-resistant prostate cancer. Proceedings of the ASCO Meeting, Chicago, Illinois, June 2010. [Abstract 4550].
27. Osoba D., Tannock I.F., Ernst D.S., et al. Health-related quality of life in men with metastatic prostate cancer treated with prednisone alone or mitoxantrone and prednisone. J Clin Oncol 1999, 17:1654-1663.
28. Tannock I.F., Osoba D., Stockler M.R., et al. Chemotherapy with mitoxantrone plus prednisone or prednisone alone for symptomatic hormone-resistant prostate cancer: A Canadian randomized trial with palliative end points. J Clin Oncol 1996, 14:1756-1764.
29. Tannock I.F., de Wit R., Berry W.R., et al. Docetaxel plus prednisone or mitoxantrone plus prednisone for advanced prostate cancer. N Engl J Med 2004, 351:1502-1512.
30. Berthold D.R., Pond G.R., de Wit R., et al. Survival and PSA response of patients in the TAX 327 study who crossed over to receive docetaxel after mitoxantrone or vice versa. Ann Oncol 2008, 19:1749-1753.
31. Petrylak D.P., Tangen C.M., Hussain M.H., et al. Docetaxel and estramustine compared with mitoxantrone and prednisone for advanced refractory prostate cancer. N Engl J Med 2004, 351:1513-1520.
32. Ernst D.S., Tannock I.F., Winquist E.W., et al. Randomized, double-blind, controlled trial of mitoxantrone/prednisone and clodronate vs. mitoxantrone/prednisone and placebo in patients with hormone-refractory prostate cancer and pain. J Clin Oncol 2003, 21:3335-3342.
33. Rosenberg J.E., Weinberg V.K., Kelly W.K., et al. Activity of second-line chemotherapy in docetaxel-refractory hormone-refractory prostate cancer patients: Randomized phase 2 study of ixabepilone or mitoxantrone and prednisone. Cancer 2007, 110:556-563.
34. Michels J., Montemurro T., Murray N., et al. First- and second-line chemotherapy with docetaxel or mitoxantrone in patients with hormone-refractory prostate cancer: Does sequence matter?. Cancer 2006, 106:1041-1046.
35. de Bono J.S., Oudard S., Ozguroglu M., et al. Prednisone plus cabazitaxel or mitoxantrone for metastatic castration-resistant prostate cancer progressing after docetaxel treatment: A randomized open-label trial. Lancet 2010, 376:1147-1154.
36. Attard G., Reid A.H., Yap T.A., et al. Phase I clinical trial of a selective inhibitor of CYP17, abiraterone acetate, confirms that castration-resistant prostate cancer commonly remains hormone driven. J Clin Oncol 2008, 26:4563-4571.
37. Attard G., Reid A.H., A'Hern R., et al. Selective inhibition of CYP17 with abiraterone acetate is highly active in the treatment of castration-resistant prostate cancer. J Clin Oncol 2009, 27:3742-3748.
38. Attard G., Reid A.H., Olmos D., et al. Antitumor activity with CYP17 blockade indicates that castration-resistant prostate cancer frequently remains hormone driven. Cancer Res 2009, 69:4937-4940.
39. Reid A.H., Attard G., Danila D.C., et al. Significant and sustained antitumor activity in post-docetaxel, castration-resistant prostate cancer with the CYP17 inhibitor abiraterone acetate. J Clin Oncol 2010, 28:1489-1495.
40. de Bono J.S., Logothetis C.J., Molina A., et al. Abiraterone and increased survival in metastatic prostate cancer. N Engl J Med 2011, 364:1995-2005.
41. Fizazi K., Carducci M., Smith M., et al. Denosumab vs. zoledronic acid for treatment of bone metastases in men with castration-resistant prostate cancer: A randomized, double-blind study. Lancet 2011, 377:813-822.
42. Stopeck A.T., Lipton A., Body J.J., et al. Denosumab compared with zoledronic acid for the treatment of bone metastases in patients with advanced breast cancer: A randomized, double-blind study. J Clin Oncol 2010, 28:5132-5139.
43. Henry D.H., Costa L., Goldwasser F., et al. Randomized, double-blind study of denosumab vs. zoledronic Acid in the treatment of bone metastases in patients with advanced cancer (excluding breast and prostate cancer) or multiple myeloma. J Clin Oncol 2011, 29:1125-1132.
44. Positive outcome of interim analysis of pivotal alpharadin study: Primary endpoint met in phase II ALSYMPA study [press release] Algeta, Last Update: June 6, 2011, Accessed Aug 11, 2011. http://hugin.info/134655/R/1521246/457913.pdf.
45. Longo D.L. New therapies for castration-resistant prostate cancer. N Engl J Med 2010, 363:479-481.
46. Tran C., Ouk S., Clegg N.J., et al. Development of a second-generation antiandrogen for treatment of advanced prostate cancer. Science 2009, 324:787-790.
47. Scher H.I., Beer T.M., Higano C.S., et al. Antitumor activity of MDV3100 in castration-resistant prostate cancer: A phase 1-2 study. Lancet 2010, 375:1437-1446.
48. Agus DB, Stadler WM, Shevrin DH, et al. Safety, efficacy, and pharmacodynamics of the investigational agent TAK-700 in metastatic castration resistant prostate cancer (mCRPC): Updated data from a phase I/II study. Proceedings of the ASCO Meeting, Chicago, Illinois, June 2011 [Abstracts 29].
49. O'Mahony D., Morris J.C., Quinn C., et al. A pilot study of CTLA-4 blockade after cancer vaccine failure in patients with advanced malignancy. Clin Cancer Res 2007, 13:958-964.
50. Leach D.R., Krummel M.F., Allison J.P. Enhancement of antitumor immunity by CTLA-4 blockade. Science 1996, 271:1734-1736.
51. Kwon E.D., Hurwitz A.A., Foster B.A., et al. Manipulation of T cell co-stimulatory and inhibitory signals for immunotherapy of prostate cancer. Proc Natl Acad Sci U S A 1997, 94:8099-8103.
52. Kwon E.D., Foster B.A., Hurwitz A.A., et al. Elimination of residual metastatic prostate cancer after surgery and adjunctive cytotoxic T lymphocyte-associated antigen 4 (CTLA-4) blockade immunotherapy. Proc Natl Acad Sci U S A 1999, 96:15074-15079.
53. Small E.J., Tchekmedyian N.S., Rini B.I., et al. A pilot trial of CTLA-4 blockade with human anti-CTLA-4 in patients with hormone-refractory prostate cancer. Clin Cancer Res 2007, 13:1810-1815.
54. Slovin SF, Beer TM, Higano CS, et al., and Prostate Cancer Clinical Trials Consortium. Initial phase II experience of ipilimumab (IPI) alone and in combination with radiotherapy (XRT) in patients with metastatic castration-resistant prostate cancer (mCRPC). Proceedings of the ASCO Meeting, Orlando, Florida, May 29-June 2, 2009 [Abstract 5138].
55. Nilsson S., Larsen R.H., Fossa S.D., et al. First clinical experience with &;α-emitting radium-223 in the treatment of skeletal metastases. Clin Cancer Res 2005, 11:4451-4459.
56. Nilsson S., Franzen L., Parker C., et al. Bone-targeted radium-223 in symptomatic, hormone-refractory prostate cancer: A randomized, multicenter, placebo-controlled phase II study. Lancet Oncol 2007, 8:587-594.
57. Scher HI, Chi KN, De Wit R, et al. Docetaxel (D) plus high-dose calcitriol vs. D plus prednisone (P) for patients (Pts) with progressive castration-resistant prostate cancer (CRPC): Results from the phase III ASCENT2 trial. Proceedings of the ASCO Meeting, Chicago, Illinois, June 2010 [Abstract 4509].
58. Small E, Demkow T, Gerritsen WR, et al. A phase III trial of GVAX immunotherapy for prostate cancer in combination with docetaxel vs. docetaxel plus prednisone in symptomatic, castration-resistant prostate cancer (CRPC). Proceedings of the Genitourinary Cancers Symposium, Orlando, Florida, February 2009 [Abstract 7].
59. Kelly WK, Halabi S, Carducci MA, et al., and Cancer and Leukemia Group. A randomized, double-blind, placebo-controlled phase III trial comparing docetaxel, prednisone, and placebo with docetaxel, prednisone, and bevacizumab in men with metastatic castration-resistant prostate cancer (mCRPC): Survival results of CALGB 90401. Proceedings of the ASCO Meeting, Chicago, Illinois, June 2010 [Abstract LBA4511].
60. de Bono J.S., Logothetis C.J., Fizazi K., et al. Abiraterone acetate (AA) plus low dose prednisone (P) improves overall survival (OS) in patients (PTS) with metastatic castration-resistant prostate cancer (mCRPC) who have progressed after docetaxel-based chemotherapy (CHEMO): Results of COU-AA-301, a randomized double-blind placebo-controlled phase III study. Ann Oncol 2010, Abstract LBA5.